A University of Colorado professor who experienced a funding freeze firsthand this year expressed relief at the program's preservation.

Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following ...

Kenya has been picked among nine countries for the trials of the new injectable HIV prevention drug that has been rolled out ...

The third study, Twiga , is an ongoing five-year observational study tracking comorbidities in both HIV-positive and HIV-negative individuals aged 60 and above. It was initiated to better understand ...

Kenya is among nine African countries, under the low- and middle-income category, that are set to be among the early beneficiaries of lenacapavir, a long-acting HIV prevention drug, following a recent ...

Kenya is set to introduce a revolutionary injectable HIV prevention drug, Lenacapavir, becoming one of nine African nations ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention as a tool ...

Integrating people-centered HIV care with primary health care is essential to improving access, equity and health outcomes, but doing so successfully requires coordinated policies, digital ...

Kenya’s femicide crisis is so pervasive that even female police officers are not immune –– such as victim and mother-of-two ...

Lenacapavir received approval from the U.S. Food and Drug Administration (FDA) in June 2025 and has subsequently been endorsed in the updated World Health Organisation (WHO) guidelines on long-acting ...

Integrating HIV and sexual health care is essential for improving outcomes, but global stigma, funding cuts—especially the defunding of USAID—and structural barriers like limited access and political ...